Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +23.58% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +24.84% |
Morningstar's Benchmark | Russell 2000 Biotech Growth [50.00%]; Nasdaq Biotechnology Index [50.00%] | -- |
- Monthly Valuation Update and Factsheet
- Half-year Report
- Closed Period Notification
- New Investment in Jade Biosciences, Inc
- Artiva Biotherapeutics prices IPO at $167 million
- Monthly Valuation Update and Factsheet
- Baroness Blackwood Appointed as Independent NED
- Investment in Mirador Therapeutics & Santa Ana Bio
- Total Voting Rights
- Positive Data Announcement - Avidity Biosciences
More ▼
Key statistics
On Friday, RTW Biotech Opportunities Ltd (RTW:LSE) closed at 1.52, -12.14% below its 52-week high of 1.73, set on Jul 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 335.71m |
---|---|
Market cap | 508.61m USD |
Total assets | 674.78m USD |
Total expense ratio | 1.97% |
High | 1.52 |
Low | 1.52 |
Previous close | 1.52 |
Average volume | 218.11k |
---|---|
YTD Change | +8.38% |
Beta | 0.6458 |
Diluted NAV (est) | 2.01 |
Diluted NAV (last pub) | 2.01 |
Premium/Discount | -24.88% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Sep 20 2024 12:57 BST.
More ▼